Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision indicator updates from v3.8.0 to v3.8.1.
    Difference
    0.1%
    Check dated 2026-11-21T13:17:33.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for a phase II colorectal cancer study is displayed, including its treatment plan, eligibility criteria, outcomes, recruitment location, and study contacts.
    Difference
    39%
    Check dated 2026-11-07T12:43:38.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer now identifies the ClinicalTrials.gov site as revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-31T13:25:35.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    A banner announces an NIH-wide transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-24T18:50:37.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T20:47:13.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T20:56:30.000Z thumbnail image

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.